Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2016.
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016.
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016.
Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016.
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016.
Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2016:1-6..
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e45-e52..
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015.
Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy. Biol Blood Marrow Transplant. 2015..
Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013.
Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One. 2013;8(5):e64138.
Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013.